INTRODUCTION
Comparative transcriptional profiling is a common way to identify genes important for carcinogenesis, and a variety of approaches have been used. Transcriptional profiles are compared among 1) groups of patients with different types of cancer, 2) primary tumor samples and normal samples from the same patient, 3) transformed and non-transformed cell lines, 4) cell lines that do or do not overexpress an oncogene. Each of these approaches has advantages and disadvantages, but all of them have contributed to our understanding of cellular transformation and cancer.
In previous work, we identified a cancer gene signature based on the identification of genes that are differentially expressed in two isogenic models of cellular transformation (1) .
One model involves non-transformed mammary epithelial cells (MCF-10A)(2) containing ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (3). Treatment of such cells with tamoxifen rapidly induces
Src, and morphological transformation is observed within 24-36 hours (4, 5) , thereby making it possible to kinetically follow the transition between non-transformed and transformed cells. The other model consists of three isogenic cell lines derived from primary fibroblasts in a serial manner (6) : EH is immortalized by overexpression of telomerase (hTERT) and exhibits normal morphology; EL also expresses SV40 T antigens and displays an altered morphology but is not transformed; ELR also expresses oncogenic Ras (H-RasV12), and it is transformed by numerous criteria including tumor formation in mouse xenografts.
The availability of transcriptional profiles for isogenic, but biologically unrelated, models of cellular transformation makes it possible to distinguish between genes that play a relatively general role in transformation as opposed to those affected only by the specific experimental model. Indeed, the 343-gene signature derived from the combined analysis of these isogenic models is highly correlated with a wide variety of human cancers, thereby validating the clinical relevance of our experimental models (1) . Of particular interest, this 4 gene signature links cancer with a variety of inflammatory and metabolic diseases, suggesting that a common transcriptional program is involved is phenotypically disparate diseases (1) . In the breast epithelial model, transient activation of Src causes an epigenetic switch from non-transformed to transformed cells that involves a positive feedback loop that is associated with a chronic inflammatory state (5, 7) .
MicroRNAs (miRNAs) play critical roles in cancer and other biological processes by directly interacting with specific mRNAs through base pairing and then inhibiting expression of the target genes through a variety of molecular mechanisms (8) (9) (10) . In the breast epithelial (ER-Src) model, 29 miRNAs are differentially regulated during the process of transformation, and many of these are important for transformation (5, 7) . In particular, down-regulation of the Let-7 family, and induction of miR-21 and miR-181b are part of the inflammatory feedback loop necessary for the establishment and maintenance of the transformed state. In addition, 22 miRNAs are differentially expressed in cancer stem cells and non-stem cancer cells that arise during the transformation process (11) , with the miR-200 family being particularly important for the function of cancer stem cells via repression of polycomb complexes (12) (13) (14) .
Here, we perform miRNA profiling in the fibroblast model of cellular transformation and identify 22 differentially regulated miRNAs, 7 of which are similarly regulated in the breast epithelial system. We focus here on miR-193a, which is highly down-regulated during transformation of both the ER-Src and fibroblast models. MiR-193a is down-regulated in oral cancer via DNA hypermethylation (15) , and it is poorly expressed in melanomas containing a B-Raf mutation (16) . The related miR-193b is 88% identical to miR-193a, but is encoded by a separate gene that is regulated differently. MiR-193b has been implicated as a tumor suppressor in breast (17) , prostate (18) , and hepatocellular cancers (19) , but high levels of miR-193b are associated with poor prognosis of malignant melanomas (16) .
We define a molecular pathway in which expression of miR-193a is directly inhibited by RXRα and Max, thereby leading to increased expression of PLAU and K-Ras, which are 5 direct targets of miR-193a. Furthermore, we show that PLAU and K-Ras have distinct roles in transformation, with PLAU affecting invasiveness, while K-Ras affects tumorigenicity.
MiR-193a acts as a tumor suppressor in developmental diverse cancer cell lines, and miR193a expression is inversely correlated with both PLAU and K-Ras in human colon adenocarcinomas, suggesting that this pathway is important for some types of human cancer. 
MATERIALS AND METHODS

Cell culture
MCF-10A cells containing the ER-Src fusion protein were grown in DMEM/F12 medium supplemented with 5% donor HS, 20 ng/ml epidermal growth factor (EGF), 10 mg/ml insulin, 100 mg/ml hydrocortisone, 1 ng/ml cholera toxin, and 50 units/ml pen/strep, with the addition of puromycin (4, 5) . Cells were passaged fewer than three months from resuscitation from the originally described cells (4, 5) . To induce transformation, the Src oncogene was activated by the addition of 1 mM tamoxifen (Sigma, St. Louis) to confluent cell cultures. BJ fibroblast cell lines were grown in KO-DMEM media containing 14% FBS, Medium 199 glutamine, and pen/strep (6) . All other cancer cell lines were obtained from ATCC and grown in DMEM, 10% FBS, and pen/strep; cells were passaged fewer than three months from resuscitation.
MicroRNA expression analysis
Expression levels of 365 microRNAs at various times after TAM addition and from nontransformed and transformed fibroblasts were evaluated with microRNA profiling assays (TLDA human miRNA v1.0) in the Dana Farber Molecular Diagnostics Facility. Validation of these results was performed using the mirVana qRT-PCR miRNA Detection Kit and qRT-PCR Primer Sets, according to the manufacturer's instructions (Ambion Inc.; Austin, TX).
RNU48 expression was used as an internal control.
Soft agar colony and invasion assays for the effect of miRNAs on transformation
For the genetic screen to identify miRNAs that act as tumor suppressors, the transformed fibroblast line (ELR) was treated individually with 365 miRNAs (100 nM) for 24 hr. For other experiments, miR-193a (PM11123), miR-193b (PM12383) or a miR-negative control (AM17110) from Ambion, Inc, TX were introduced at 100 nM into a variety of breast and other types of cancer cell lines for 24 hr. In the case of ER-Src cells, TAM was added and cellular transformation was assessed 36 hr later (total time 60 hr). The soft agar colony and MATRIGEL invasion assays were performed as described previously (1, 5) . In all cases, experiments were repeated thrice, and the statistical significance was calculated using Student's t test.
RNA analysis
For samples generated in this work, RNA was purified by the Trizol method (Invitrogen, Carlsbad, CA), reverse transcribed to generate cDNA, and analyzed by SYBR Green-based real-time PCR, with the level of β-actin used as a loading control. RNAs from colon adenocarcinomas (Origene and Biochain Inc.; Rockville, MD) were analyzed for levels of PLAU, K-Ras and miR-193a. Each sample was run in triplicate, and the data represent the mean ± SD. Correlation coefficients between PLAU, K-Ras and miR-193a expression levels in these colon adenocarcinomas were determined.
3'UTR luciferase assay
Firefly luciferase reporter constructs containing the 3' UTR of PLAU (s207136 from Switchgear Genomics) and K-Ras (HmiT010133 from Genecopoeia Inc) were transfected in MCF10A ER-Src cells along with 100 nM miR-193a or a miRNA control. Cell extracts were prepared 24h after transfection, and luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega, WI, USA).
siRNA experiments
Cells seeded in 6-well plates were transfected with siRNAs against PLAU (s10610), K-Ras 
RESULTS
Differentially regulated miRNAs during transformation in the isogenic fibroblast model
In previous work, we performed microRNA profiling in an inducible model cellular transformation in breast epithelial cells and identified 29 differentially expressed miRNAs during the transformation process (7). Here, we performed a similar miRNA profiling analysis in 3 cell isogenic cell lines derived from primary fibroblasts that are immortalized family are down-regulated in both models.
MiRNAs that inhibit tumorigenicity of transformed fibroblasts
As a genetic screen to identify miRNAs that function as tumor suppressors in the fibroblast model, we individually overexpressed 365 miRNAs in the transformed fibroblasts fibroblast model. Importantly, miR-148b, miR-335, miR-193a and the Let-7 family members also inhibit transformation in the breast epithelial system (7), suggesting that these miRNAs function as tumor suppressors in multiple cell types. In this paper, we focus on miR-193a, because molecular pathways involving this miRNA are essentially unknown.
MiR-193a down-regulation is important for tumorigenicity and invasive growth in genetically distinct breast cancer cell lines
As shown here ( Fig. 1 ) and elsewhere (7), miR-193a is down-regulated during transformation and important for tumorigenicity in both the fibroblast and breast epithelial models. To extend these findings, we analyzed miR-193a and miR-193b expression and function in genetically distinct breast cancer cell lines. In non-transformed MCF-10A cells, miR-193a and miR-193b levels are roughly comparable, with perhaps slightly higher levels for miR-193b ( Fig. 2A) . In all breast cancer cell lines tested, miR-193a is expressed in lower levels than in immortalized, non-transformed breast cells ( Fig. 2A) . Furthermore, in all breast cancer cell lines tested, miR-193a overexpression significantly reduces colony formation in soft agar (Fig. 2B) . Lastly, over-expression miR-193a in these breast cancer cells reduces the number of invading cells in a MATRIGEL assay (Fig. 2C ). In comparison, levels of miR193b are more consistent (although not identical) among the cell lines, and the effects on colony formation are less pronounced (Figs. 2A, B) . Thus, miR-193a inhibits cellular transformation by limiting anchorage-independent growth and reducing invasiveness.
MiR-193a regulates directly the expression of PLAU and K-RAS in breast cancer cells
To investigate how miR-193a exerts its anti-cancer effects, we generated a list of candidate target genes using three prediction algorithms (PicTar, TargetScan, Sanger) based on sequence complementarity to 3'-untranslated regions (3' UTR). Among these candidate target genes, PLAU and K-Ras expression is up-regulated, and hence inversely correlated, with miR-193a expression in both transformation models. Furthermore, during the process of cellular transformation in the inducible breast epithelial model, expression of both PLAU (Fig. 3A) and K-Ras (Fig. 3B ) gradually increases in parallel to decreasing expression of miR-193a. In the transformed state (36 hr after tamoxifen induction), PLAU is expressed 7-fold higher and K-Ras is expressed 5-fold higher than the level in cells prior to transformation. The inverse expression of miR-193a with both PLAU and K-Ras is consistent with these genes being relevant targets during transformation.
The 3' UTRs of both PLAU and K-Ras have an 8-bp sequence that is perfectly complementary with miR-193a (Fig. 3C) , and the PLAU 3' UTR is required for inhibition by the related miR-193b (17) . Over expression of miR-193a in MCF-10A ER-Src cells down regulates the luciferase activity of reporter construct containing either the PLAU or K-Ras 3-UTR (Fig. 3C ). This shows that miR-193a binds directly to these target RNAs and inhibits PLAU and K-Ras expression through 3'UTR base pairing. In addition, overexpression of miR-193a in all breast cancer cell lines tested (which all have low levels of miR-193a; Fig.   2A ) significantly inhibits both PLAU and K-Ras expression (Fig. 3D) . These results indicate that miR-193a directly inhibits PLAU and K-Ras expression.
MiR-193a controls tumorigenicity through K-Ras and invasiveness through PLAU
PLAU is a metastasis-associated protein that supports cell migration and matrixproteases activity (20) , and K-Ras is involved in many oncogenic functions, such as antiapoptotic activity, angiogenesis, motility, and cell growth (21) . To address the roles PLAU and K-Ras play in breast cell transformation, we inhibited the expression of either one these genes (by siRNA; Fig. S2 ) and miR-193a or miR-193b (by antisense RNA) in MDA-MB-231 breast cancer cells and measured tumorigenicity and invasiveness. As expected, inhibition of miR-193a results in both increased tumorigenicity (Fig. 4A ) and increased invasiveness, (Fig. 4B) whereas inhibition of miR-193b has little effect. In the context of reduced levels of miR-193a, inhibition of K-Ras reduced tumorigenicity (colony formation in soft agar), whereas inhibition of PLAU had no significant effect (Fig. 4A) . In contrast, inhibition of PLAU blocked the increased invasiveness due to inhibition of miR-193a, while inhibition of K-Ras has no effect (Fig. 4B ). These observations suggest that miR-193a controls the tumorigenicity of breast cancer cells through regulation of K-Ras while it affects their invasiveness through regulation of PLAU.
Max and RXRα bind directly to the miR-193a promoter and inhibit miR-193a expression during transformation
The reduced expression of miR-193a expression during transformation is likely due to a transcription factor(s) that bind to specific DNA sequences in the miR-193a promoter and acts, formally, as a transcriptional repressor. We previously used the Lever algorithm (22) Using siRNA-mediated inhibition, we examined the effect of Max and RXRα on transcription of miR-193a at various times during the transformation process (Fig. 5C ). We also examined the effect of Max and RXRα on expression of the other miRNAs whose promoters are bound by these transcription factors (Fig. 5E) . As observed for miR193a, repression of miR-148a and miR-148b in transformed cells (36 hours after TAM treatment) is blocked by inhibition of Max and mildly alleviated by inhibition of RXRα. In contrast, miR-181b is induced in transformed cells, and this induction is blocked by the combined inhibition of Max and RXRα. Individually, both Max and RXRα are important for miR-181b induction, with RXRα having a stronger influence on expression levels (Fig.   5E ). Thus, the combination of Max and RXRα directly regulate expression of target miRNA promoters, although regulation can be either positive or negative depending on the target.
MiR-193a inhibits tumorigenicity of multiple, but not all, cancer cell types
To examine whether miR-193a affects tumorigenicity of non-breast cancer cell types, we over-expressed miR-193a in a variety of cancer cells from diverse developmental lineages. In addition to its effects on all breast cancer cell lines tested (Fig. 2) expression levels than cell lines not showing this effect (Fig. 6B) . This observation suggests that miR-193a is a tumor suppressor in most (and perhaps all) cancer cell types, but that detection of this function occurs only in cell types with reduced miR-193a levels that can be compensated by ectopic expression of miR-193a.
MiR-193a acts as a tumor suppressor in mouse xenografts
To examine whether miR-193a acts as tumor suppressor in vivo, we injected nude mice subcutaneously with colorectal (HCT-116 and HT-29) and breast (MDA-MB-231) cancer cells and allowed tumors to develop for 10 days. We then performed i.p. injection of miR193a or a negative control miRNA near these small tumors (3 cycles on days 10, 15, 20) and monitored tumor size every five days. Over the course of a month, mice treated with miR193a show reduced tumor growth as compared to mice treated with the control (Fig. 6C) .
Thus, miR-193a suppresses tumor growth in mouse xenografts generated by breast and colorectal cancer cells, indicating that low levels of miR-193a are required to maintain transformation in these cell types.
MiR-193a levels are negatively correlated with PLAU and K-Ras in cancer tissues
In previous studies, we established the cancer relevance of miRNA-target interactions by determining the relationship between their RNA levels in human cancer patients (5, 7, 12) .
Specifically, an inverse correlation between miRNA and target mRNA levels in a set of cancer patients indicates that the miRNA-target interaction (as opposed to the miRNA or target individually) plays an important role in human cancer. In this regard, there are strong inverse relationships between miR-193a and PLAU RNA levels as well as miR-193a and KRas RNA levels in colon cancer patients (Fig. 6D) . Thus, miR-193a regulation of PLAU and K-Ras is relevant for at least some types of cancer. 
DISCUSSION
In this work, we describe a gene regulatory pathway involved in cellular transformation (Fig. 7) . In this pathway, Max and (to a lesser extent) RXRα, directly binds the miR-193a promoter and inhibits transcription of the gene. The resulting reduction in miR-193a levels leads to increased expression of PLAU and K-Ras, which are direct targets of miR-193a.
Increased levels of PLAU and K-Ras contribute to distinct aspects of cellular transformation, with PLAU being important for the invasive growth and K-Ras being important for tumorigenicity.
The combination of Max and RXRα binding motifs is strongly enriched in miRNA promoters whose expression is differentially regulated during transformation (7). Indeed, 
